← Leaderboards
Eli Ipp
La Biomed Res Inst/ Harbor Ucla Med Ctr
$4,045,857
Attributed
$4,045,857
Total exposure
47
Grants
33
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $807.4K · FY2005–10$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$4,045,857 · 47
By mechanism
M01$4,045,857 · 47
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchInsulinHuman SubjectUnited States National Institutes Of HealthSourceComputer Retrieval Of Information On Scientific Projects DatabaseResourcesResearch PersonnelGrantFundingInstitutionDiabetes MellitusBlood GlucoseGenesInsulin SecretionDiabetes Mellitus, Non-Insulin-DependentHypoglycemiaNoninsulin Dependent Diabetes MellitusGlucoseNon-Insulin-Dependent Diabetes MellitusFastingInjection /InfusionFollow-UpDiagnosis Quality /Standard
Grant awards (66)
INSULINOPENIC TYPE 2 DIABETES IN HISPANICS$344,785
M01 · FY2010 · RR · contact PI
GENETICS OF DIABETIC RETINOPATHY IN HISPANICS$275,533
M01 · FY2010 · RR · contact PI
EVALUATION AND MECHANISMS IN INSULIN SECRETING TUMORS$82,016
M01 · FY2010 · RR · contact PI
BETA CELL COMPENSATORY FACTORS IN INSULIN RESISTANCE$79,251
M01 · FY2010 · RR · contact PI
ACQUISITION CENTER FOR GENNID PROJECT$23,037
M01 · FY2010 · RR · contact PI
TRANSPLANTATION ALONE (ITA) IN PATIENTS WITH DIFFICULT CONTROL TYPE I DIABETE$2,765
M01 · FY2010 · RR · contact PI
INSULINOPENIC TYPE 2 DIABETES IN HISPANICS$401,664
M01 · FY2009 · RR · contact PI
GENETICS OF DIABETIC RETINOPATHY IN HISPANICS$153,573
M01 · FY2009 · RR · contact PI
ACQUISITION CENTER FOR GENNID PROJECT$61,429
M01 · FY2009 · RR · contact PI
EVALUATION AND MECHANISMS IN INSULIN SECRETING TUMORS$43,746
M01 · FY2009 · RR · contact PI
BETA CELL COMPENSATORY FACTORS IN INSULIN RESISTANCE$14,891
M01 · FY2009 · RR · contact PI
MEXICAN AMERICAN ADMIXTURE MAPPING DEVELOPMENT AND APPLICATION TO NIDDM (NON-$13,961
M01 · FY2009 · RR · contact PI
TRANSPLANTATION ALONE (ITA) IN PATIENTS WITH DIFFICULT CONTROL TYPE I DIABETE$5,584
M01 · FY2009 · RR · contact PI
INSULINOPENIC TYPE 2 DIABETES IN HISPANICS$214,097
M01 · FY2008 · RR · contact PI
ACQUISITION CENTER FOR GENNID PROJECT$46,781
M01 · FY2008 · RR · contact PI
MEXICAN AMERICAN ADMIXTURE MAPPING DEVELOPMENT AND APPLICATION TO NIDDM (NON-$18,273
M01 · FY2008 · RR · contact PI
EVALUATION AND MECHANISMS IN INSULIN SECRETING TUMORS$13,157
M01 · FY2008 · RR · contact PI
GENETICS OF DIABETIC RETINOPATHY IN HISPANICS$13,157
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: INSULIN RESISTANCE IN THE ISLETS OF LANGERHANS$12,427
M01 · FY2008 · RR · contact PI
ISLET CELL TRANSPLANTATION ALONE (ITA)$2,193
M01 · FY2008 · RR · contact PI
BETA CELL COMPENSATORY FACTORS IN INSULIN RESISTANCE$1,463
M01 · FY2008 · RR · contact PI
INSULINOPENIC TYPE 2 DIABETES IN HISPANICS$126,689
M01 · FY2007 · RR · contact PI
EVALUATION AND MECHANISMS IN INSULIN SECRETING TUMORS$51,122
M01 · FY2007 · RR · contact PI
INSULIN RESISTANCE IN THE ISLETS OF LANGERHANS$44,640
M01 · FY2007 · RR · contact PI
ACQUISITION CENTER FOR GENNID PROJECT$33,480
M01 · FY2007 · RR · contact PI
MEXICAN AMERICAN ADMIXTURE MAPPING DEVELOPMENT AND APPLICATION TO NIDDM (NON-$19,442
M01 · FY2007 · RR · contact PI
TRANSPLANTATION ALONE (ITA) IN PATIENTS WITH DIFFICULT CONTROL TYPE I DIABETE$3,241
M01 · FY2007 · RR · contact PI
INSULIN RESISTANCE IN THE ISLETS OF LANGERHANS$109,640
M01 · FY2006 · RR · contact PI
INSULINOPENIC TYPE 2 DIABETES IN HISPANICS$100,758
M01 · FY2006 · RR · contact PI
EVALUATION AND MECHANISMS IN INSULIN SECRETING TUMORS$77,915
M01 · FY2006 · RR · contact PI
ACQUISITION CENTER FOR GENNID PROJECT$28,174
M01 · FY2006 · RR · contact PI
TRANSPLANTATION ALONE (ITA) IN PATIENTS WITH DIFFICULT CONTROL TYPE I DIABETE$9,350
M01 · FY2006 · RR · contact PI
MEXICAN AMERICAN ADMIXTURE MAPPING DEVELOPMENT AND APPLICATION TO NIDDM (NON-$623
M01 · FY2006 · RR · contact PI
INSULIN RESISTANCE IN THE ISLETS OF LANGERHANS$189,895
M01 · FY2005 · RR
INSULINOPENIC TYPE 2 DIABETES IN HISPANICS$129,717
M01 · FY2005 · RR
EVALUATION AND MECHANISMS IN INSULIN SECRETING TUMORS$45,393
M01 · FY2005 · RR
ACQUISITION CENTER FOR GENNID PROJECT$38,552
M01 · FY2005 · RR
TRANSPLANTATION ALONE (ITA) IN PATIENTS WITH DIFFICULT CONTROL TYPE I DIABETE$13,240
M01 · FY2005 · RR
Insulin Resistance in the Islets of Langerhans$137,169
M01 · FY2004 · RR
Evaluation and Mechanisms in Insulin Secreting Tumors$52,634
M01 · FY2004 · RR
Acquisition Center for GENNID Project$39,154
M01 · FY2004 · RR
Randomized, Multicenter, Double-Blind, Placebo Controlled Study with Two Para...$8,344
M01 · FY2004 · RR
HNF-1 a Polymorphism in Mexican Americans: Effect on Insulin Secretion$5,136
M01 · FY2004 · RR
Microvascular Disease of the Heart in Type 2 Diabetes Mellitus$1,926
M01 · FY2004 · RR
INSULIN SECRETING TUMORS--IMPROVED DIAGNOSTIC APPROACHES$237,978
M01 · FY2001 · RR
CASE MANAGEMENT IN NIDDM$237,978
M01 · FY2001 · RR
DIABETES PREVENTION PROTOCOL--TYPE 1$237,978
M01 · FY2001 · RR
CENTRAL CONTROL OF GLUCOSE HOMEOSTASIS--STUDIES OF GLUCOSE THRESHOLD$237,978
M01 · FY2001 · RR
DIABETES PREVENTION PROTOCOL--TYPE 1$982
M01 · FY2000 · RR
CENTRAL CONTROL OF GLUCOSE HOMEOSTASIS--STUDIES OF GLUCOSE THRESHOLD$982
M01 · FY2000 · RR
INSULIN SECRETING TUMORS--IMPROVED DIAGNOSTIC APPROACHES$982
M01 · FY2000 · RR
CASE MANAGEMENT IN NIDDM$982
M01 · FY2000 · RR
Physiological characterization of NIDDM$0
M01 · FY2000 · RR
Physiological characterization of NIDDM$0
M01 · FY2000 · RR
Physiological characterization of NIDDM$0
M01 · FY2000 · RR
CASE MANAGEMENT IN NIDDM$0
M01 · FY2000 · RR
CASE MANAGEMENT IN NIDDM$0
M01 · FY2000 · RR
DIABETES PREVENTION PROTOCOL--TYPE 1$0
M01 · FY2000 · RR
DIABETES PREVENTION PROTOCOL--TYPE 1$0
M01 · FY2000 · RR
CENTRAL CONTROL OF GLUCOSE HOMEOSTASIS--STUDIES OF GLUCOSE THRESHOLD$0
M01 · FY2000 · RR
CENTRAL CONTROL OF GLUCOSE HOMEOSTASIS--STUDIES OF GLUCOSE THRESHOLD$0
M01 · FY2000 · RR
INSULIN SECRETING TUMORS--IMPROVED DIAGNOSTIC APPROACHES$0
M01 · FY2000 · RR
INSULIN SECRETING TUMORS--IMPROVED DIAGNOSTIC APPROACHES$0
M01 · FY2000 · RR
Androgen ablation and comorbid disease in prostate cancer$0
M01 · FY2000 · RR
Androgen ablation and comorbid disease in prostate cancer$0
M01 · FY2000 · RR
Androgen ablation and comorbid disease in prostate cancer$0
M01 · FY2000 · RR